Niramol Savaraj
About
In The Last Decade
Niramol Savaraj
210 papers receiving 6.8k citations
Peers
Comparison fields: 5 of 127
- Molecular Biology 3.2k
- Oncology 2.4k
- Cancer Research 1.7k
- Biotechnology 1.1k
- Pulmonary and Respiratory Medicine 741
Countries citing papers authored by Niramol Savaraj
This map shows the geographic impact of Niramol Savaraj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niramol Savaraj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niramol Savaraj more than expected).
Fields of papers citing papers by Niramol Savaraj
This network shows the impact of papers produced by Niramol Savaraj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niramol Savaraj. The network helps show where Niramol Savaraj may publish in the future.
Co-authorship network of co-authors of Niramol Savaraj
This figure shows the co-authorship network connecting the top 25 collaborators of Niramol Savaraj. A scholar is included among the top collaborators of Niramol Savaraj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niramol Savaraj. Niramol Savaraj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 41 | |
| 2 | 14 | |
| 3 | 35 | |
| 4 | 0 | |
| 5 | 67 | |
| 6 | 67 | |
| 7 | 30 | |
| 8 | Inhibition of mTOR activity potentiates 2-DG-induced cell death in hypoxic cells via down-regulation of HIF-1α | 1 |
| 9 | Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells | 6 |
| 10 | G-quartet oligonucleotides: A new class of Stat3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis | 13 |
| 11 | 21 | |
| 12 | 25 | |
| 13 | 4 | |
| 14 | Compassionate use of oral piritrexim in advanced bladder cancer an effective drug after progression on mvac chemotherapy | 1 |
| 15 | 2 | |
| 16 | Pharmacokinetics of caracemide (CAR, NSC-253272) in dogs | 2 |
| 17 | Comparison of CSF penetration of VP-16 by intracarotid (IC) intravenous (IV) and intraventricular route (IT) in dogs | 1 |
| 18 | Interaction of [3H]homoharringtonine (HHT) with the calcium antagonist receptor in the rat | 1 |
| 19 | Clinical pharmacology and intracerebral tumor penetration of 4'-demethyl epipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside) (VP-16, NSC-141540) | 5 |
| 20 | Effects of cimetidine on the clinical pharmacokinetics of 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone (AZQ, NSC-182986) | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.